PH12014501224B1 - Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate - Google Patents

Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate

Info

Publication number
PH12014501224B1
PH12014501224B1 PH12014501224A PH12014501224A PH12014501224B1 PH 12014501224 B1 PH12014501224 B1 PH 12014501224B1 PH 12014501224 A PH12014501224 A PH 12014501224A PH 12014501224 A PH12014501224 A PH 12014501224A PH 12014501224 B1 PH12014501224 B1 PH 12014501224B1
Authority
PH
Philippines
Prior art keywords
dihydroquinoline
isoindole
difluoromethoxy
cyclopropyl
dihydro
Prior art date
Application number
PH12014501224A
Other versions
PH12014501224A1 (en
Inventor
Sahoe Kakuda
Tsutomu Miyazaki
Kotaro Okada
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of PH12014501224B1 publication Critical patent/PH12014501224B1/en
Publication of PH12014501224A1 publication Critical patent/PH12014501224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

(1) A tablet according to the present invention has a percentage content of 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2, 3-dihydro-1H-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonic acid hydrate of between 80 wt pcnt and 97.5 wt pcnt . (2) The tablet is smaller in size than 200mg of a commercially available Geninax tablet. (3) As a result, drug compliance is improved, (4) leachability is high, and (5) hardness and friability are high. (6) As a result, the present invention withstands film coating and transportation, and is useful as a tablet of methanesulfonic acid hydrate of chemical compound A.
PH12014501224A 2011-11-30 2014-05-30 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate PH12014501224A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011261727 2011-11-30
PCT/JP2012/080887 WO2013081044A1 (en) 2011-11-30 2012-11-29 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonic acid hydrate

Publications (2)

Publication Number Publication Date
PH12014501224B1 true PH12014501224B1 (en) 2014-09-08
PH12014501224A1 PH12014501224A1 (en) 2014-09-08

Family

ID=48535494

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014501224A PH12014501224A1 (en) 2011-11-30 2014-05-30 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate

Country Status (10)

Country Link
JP (1) JP6117112B2 (en)
CN (2) CN109662952A (en)
BR (1) BR112014012994A2 (en)
MX (1) MX350659B (en)
MY (1) MY169750A (en)
PH (1) PH12014501224A1 (en)
RU (1) RU2633477C2 (en)
SG (1) SG11201402597WA (en)
WO (1) WO2013081044A1 (en)
ZA (1) ZA201403942B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201717949A (en) * 2015-10-29 2017-06-01 日本臟器製藥股份有限公司 Tablet containing fexofenadine as an active ingredient
JP6600084B2 (en) * 2016-04-27 2019-10-30 富士フイルム富山化学株式会社 Tablets containing tosufloxacin tosylate, disintegrant and acidic amino acid
JP7058104B2 (en) * 2017-10-19 2022-04-21 日本化薬株式会社 Pharmaceutical tablets containing aprepitant as an active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
ES2229786T3 (en) * 1998-11-10 2005-04-16 Bayer Healthcare Ag PHARMACEUTICAL PREPARATION OF MOXIFLOXACINE.
JP4370050B2 (en) * 2000-12-04 2009-11-25 大正製薬株式会社 Clarithromycin tablets and method for producing the same
DK1459739T3 (en) * 2003-03-19 2008-05-19 Jordanian Pharmaceutical Mfg Non-hydroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
JP4702763B2 (en) * 2003-07-30 2011-06-15 塩野義製薬株式会社 Stable tablets containing crystalline cellulose
ES2320360T3 (en) * 2004-08-13 2009-05-21 Schering-Plough Ltd. PHARMACEUTICAL FORMULATION THAT INCLUDES AN ANTIBIOTIC, A TRIAZOL AND A CORTICOSTEROID.
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
FI20080352A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with high drug content
FI20080353A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with extra high drug content
JP2011068647A (en) * 2009-08-31 2011-04-07 Kowa Co Solid formulation containing aspartic acid or salt thereof
JPWO2011059075A1 (en) * 2009-11-13 2013-04-04 味の素株式会社 High content preparation of glutamic acid and arginine

Also Published As

Publication number Publication date
CN104039322A (en) 2014-09-10
RU2014126094A (en) 2016-01-27
ZA201403942B (en) 2015-08-26
WO2013081044A1 (en) 2013-06-06
PH12014501224A1 (en) 2014-09-08
JPWO2013081044A1 (en) 2015-04-27
MX2014006378A (en) 2014-10-13
MX350659B (en) 2017-09-13
SG11201402597WA (en) 2014-09-26
MY169750A (en) 2019-05-15
BR112014012994A2 (en) 2017-06-13
RU2633477C2 (en) 2017-10-12
CN109662952A (en) 2019-04-23
JP6117112B2 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2016010266A (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy] phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use.
JO3148B1 (en) Notch pathway signaling inhibitor compound
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
PH12016501328B1 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
MY180165A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
TW201611833A (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
PH12014501224B1 (en) Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate
WO2011076840A3 (en) Aerosol formulation for copd
NZ701428A (en) New alfentanil composition for the treatment of acute pain
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
MX345278B (en) Process for the synthesis of 3,4-dimethoxybicyclo[4.2.0]octa-1,3, 5-triene-7-carbonitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
MX343986B (en) Stabilized pharmaceutical compositions comprising rasagiline salts.
TH153154A (en) Tablets with 1-cyclopropyl-8- (diffluoromethoxy) -7 - ((1R) -1-methyl-2,3-dihydro-1H-iso Indole-5-il) -4-oxo-1,4-dihydroquinoline-3-carboxylic acid, methane, sulfonic acid Hydrated
MX2012014342A (en) Preparation of a levalbuterol salt.
TN2013000515A1 (en) Notch pathway signaling inhibitor compound